Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Abstract Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III CLARITY AD trial were used to estima...

Full description

Bibliographic Details
Main Authors: Ataru Igarashi, Mie Kasai Azuma, Quanwu Zhang, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kiyoyuki Tomita, Amir Abbas Tahami Monfared
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Neurology and Therapy
Subjects:
Alzheimer’s disease
Cost-effectiveness
Lecanemab
CLARITY AD
Patient-level simulator
Quality-adjusted life years
Online Access:https://doi.org/10.1007/s40120-023-00492-7

Internet

https://doi.org/10.1007/s40120-023-00492-7

Similar Items